Dan has over 20 years of experience as a leader in the pharmaceutical industry, implementing significant disruptive programs that have helped to revolutionize clinical trial conduct. These concepts were brought to the industry in ReSearch Pharmaceutical Services’ (“RPS”) Functional Service Provider (FSP) model (1998) and Embedded Solutions model (2009). For his work, Dan was awarded the Industry Innovation Award in 2012.
Dan founded RPS in 1998 and was the company’s CEO and Chairman of the Board through 2013. During his tenure, he grew RPS to approximately $500M in revenue and greater than 5,000 employees operating in over 65 countries, establishing the company as a top tier global Contract Research Organization (CRO) with an annualized growth rate of greater than 30%.
RPS went public (on the London AIM exchange) in 2008 and was subsequently taken private by Warburg Pincus in 2011, and was later acquired by KKR in 2013 and merged with PRA Health Sciences.
Prior to starting RPS, Mr. Perlman served as Executive Vice President of Operating Specialties for Romac, Inc. from 1993 to 1998 (in 1996 going public as Kforce, Inc.). While at Romac, Dan established and grew the Pharmaceutical Division (1995), Healthcare Division (1996), Engineering Division (1996), Scientific Division (1996), Legal Division (1997), and Human Resources Division (1997). During that time, Romac’s revenue grew from approximately $50M in 1995 to approximately $1 billion in 1998 when Dan left to start RPS.
As an SLP, Dan brings to Argentum extensive experience and expertise in outsourced pharmaceutical services, staffing and personnel related services.
Originally from the Philadelphia area, Dan graduated from The Haverford School (1974) and later received his MBA from the University of Pennsylvania, Wharton School of Business (1979).
ReSearch Pharmaceutical Services, Inc. (RPS) is a global, next-generation clinical research organization, or CRO, providing clinical development services to the biopharmaceutical industry. The Company’s services support the design, initiation and management of its clients’ clinical trials programs that are required to obtain regulatory approval to market biopharmaceutical products. RPS provides these services either as integrated solutions, embedded within the client’s internal clinical development operations and supporting the entire breadth of the client’s drug development pipeline, or on a more traditional project-by-project basis. RPS’s innovative, next-generation business model allows it to leverage its clients’ existing processes to improve quality, increase the speed of product development and reduce overall development costs while allowing its clients to maintain control of their development portfolio. RPS offers its services on a global basis, including in North America, Latin America, Europe and Asia, and has developed a diverse client mix including 14 of the 15 largest pharmaceutical companies in the world. RPS was acquired by affiliates of Warburg Pincus in February 2011.
Transformative Pharmaceutical Solutions (TPS) provides customized Adaptive Integrated Monitoring solutions to biopharmaceutical company sponsors and investigative sites conducting clinical trials. By leveraging “people, process and technology”, TPS addresses the inefficiencies inherent in current outsourcing strategies and the associated lack of transparency, utilizing real-time monitoring of clinical and operational data to drive quality, efficiency and cost savings. The company brings together industry leaders with over two decades of experience building and implementing integrated solutions within the Pharmaceutical Industry.